- ASSOCIATE PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
Ph.D., Institute of Basic Medical Sciences
Indian Institute of Science
Weizmann Institute of Science
The Endocrine Society
The American Thyroid Association
Five year Predoctoral Fellowship
University Grants Commission, India
The thyroid stimulating hormone receptor (TSHR) expressed on the plasma membrane of thyroid epithelial cells is central to the regulation of thyroid growth and function. TSHR undergoes complex post-translational processing such as 1) intra-molecular cleavage of the receptors into covalently linked α and β subunits and 2) homo-oligomerization. Our focus is on understanding the role of these post-translational modifications on receptor regulation and signaling using biochemical and biophysical approaches. Understanding these regulations is important in thyroid autoimmune diseases and thyroid development.
Morshed SA, Ando T, Latif R, Davies TF. Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. Endocrinology 2010 Nov; 151(11).
Latif R, Michalek K, Davies TF. Subunit interactions influence TSHR multimerization. Molecular endocrinology (Baltimore, Md.) 2010 Oct; 24(10).
Latif R, Michalek K, Morshed SA, Davies TF. A tyrosine residue on the TSH receptor stabilizes multimer formation. PloS one 2010; 5(2).
Martin AP, Marinkovic T, Canasto-Chibuque C, Latif R, Unkeless JC, Davies TF, Takahama Y, Furtado GC, Lira SA. CCR7 deficiency in NOD mice leads to thyroiditis and primary hypothyroidism. Journal of immunology (Baltimore, Md. : 1950) 2009 Sep; 183(5).
Michalek K, Morshed SA, Latif R, Davies TF. TSH receptor autoantibodies. Autoimmunity reviews 2009 Dec; 9(2).
Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinology and metabolism clinics of North America 2009 Jun; 38(2).
Ma R, Latif R, Davies TF. Thyrotropin-independent induction of thyroid endoderm from embryonic stem cells by activin A. Endocrinology 2009 Apr; 150(4).
Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 2009; 150: 519-529.
Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, Zhu LL, Iqbal J, Latif R, Natrajan A, Arabi A, Yamoah K, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A 2008; 105: 4289-4294.
Yin X, Latif R, Bahn R, Tomer Y, Davies TF. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy. Thyroid : official journal of the American Thyroid Association 2008 Nov; 18(11).
Ando T, Latif R, Davies TF. Antibody-induced modulation of TSH receptor post-translational processing. J Endocrinol 2007; 195: 179-186.
Latif R, Ando T, Davies TF. Lipid rafts are triage centers for multimeric and monomeric thyrotropin receptor regulation. Endocrinology 2007; 148: 3164-3175.
Ando T, Latif R, Davies T. Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody. JCI 2004; 113: 1589-1595.
Latif R, Ando T, Daniel S, Davies TF. Localization and Regulation of Thyrotropin Receptors within Lipid Rafts. Endocrinology 2003; 144: 4725-4728.
Ciullo I, Latif R, Graves P, Davies TF. Functional assessment of the thyrotropin receptor-beta subunit. Endocrinology 2003; 144: 3176-3181.
Latif R, Graves P, Davies TF. Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor. J Biol.Chem 2002; 277: 45059-45067.
Ando T, Latif R, Pritsker A, Moran T, Nagayama Y, Davies TF. A monoclonal thyroid-stimulating antibody. J Clin Invest 2002; 110: 1667-1674.
Davies T, Marians R, Latif R. The TSH receptor reveals itself. J.Clin.Invest 2002; 110: 161-164.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Latif did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
James J Peters Veteran Adminis Floor Floor 2F Room Room 30
130 West Kingsbridge Road
Bronx, NY 10468